scholarly journals Serum Levels of lncRNA CCHE1 and TCF21 in Patients with Coronary Artery Disease and Their Clinical Significances

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Miaomiao Liu ◽  
Ying Zhang ◽  
Xiantong Cao ◽  
Xue Wang
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Level ◽  
Cardiovascular Events ◽  
Negative Relationship ◽  
Rank Correlation ◽  
Serum Levels ◽  
Lesion Group ◽  
Artery Disease

Objective. To detect serum level changes of CCHE1 and TCF21 in coronary artery disease (CAD) patients and to explore their clinical significances. Patients and Methods. A total of 150 CAD patients were divided into the mild lesion group ( n = 52 ), moderate lesion group ( n = 48 ), and severe lesion group ( n = 50 ), respectively, according to the Gensini score. In addition, they were divided into single vessel lesion ( n = 42 ), two vessel lesions ( n = 49 ), and three vessel lesions group ( n = 59 ), respectively. Serum levels of CCHE1 and TCF21 in CAD patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Spearman’s rank correlation was conducted to assess the relationship between levels of CCHE1 and TCF21 and severity and numbers of vessel lesions in CAD. Pearson’s correlation test was used for analyzing the correlation between CCHE1 and TCF21 levels. A multivariable logistic regression test was performed to evaluate the influences of CCHE1 and TCF21 levels on CAD severity and the occurrence of cardiovascular events within 3 years of follow-up. Results. Significant differences in incidences of diabetes and hypertension were identified in CAD patients divided according to CAD severity. In addition, significant differences in incidences of drinking, diabetes, and hypertension were identified in CAD patients divided according to numbers of vessel lesions. The serum level of CCHE1 was positively related to CAD severity and numbers of vessel lesions, while TCF21 displayed a negative relationship. During the 3-year follow-up, the incidence of cardiovascular events was 39.3% (59/150). CAD severity, numbers of vessel lesions, and serum levels of CCHE1 and TCF21 were independent factors influencing the occurrence of cardiovascular events in CAD patients. Conclusions. The increased serum level of CCHE1 and decreased TCF21 level are closely related to CAD severity, which are able to influence the prognosis in CAD patients.

Serum FGF-21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease—Results from a Median Follow-Up of 4.8 Years Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 426-P
Author(s):  
YUQIAN BAO ◽  
YUN SHEN ◽  
XUELI ZHANG ◽  
YITING XU ◽  
QIN XIONG ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cardiovascular Events ◽  
Artery Disease

scholarly journals Serum Level of Interleukin-33, C-Reactive Protein, and Troponin in Iraqi Coronary Artery Disease Patients

2020 ◽  
pp. 314-321
Author(s):  
Athraa Z. Al-Obaidi ◽  
Jinan M. J. Al-Saffar
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Level ◽  
Lipid Profile ◽  
Supply And Demand ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Artery Disease

     Coronary artery disease (CAD) is a condition of an inadequate supply of oxygenated blood to a portion of the myocardium. It typically occurs when there is an imbalance between supply and demand of myocardial oxygen. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery or arteries which is sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. Fifty CAD subjects (23 females and 27 males) were enrolled in this study in addition to thirty healthy control subjects (13 female and 17 male). This study aimed to measure the serum levels of interleukin IL- 33, C- reactive protein and troponin in CAD and their association with lipid profile by using enzyme-linked immune sorbent assay (ELISA). T results showed that high-density lipoprotein (HDL) was statistically high while differences in cholesterol, triglyceride and low-density lipoprotein (LDL) were statistically non-significant between CAD patients and controls. Moreover, the serum level of IL-33 and CRP were statistically higher in patients than controls, while troponin levels were not significantly different. In addition, the present study demonstrates that IL-33, CRP, and Troponin were not associated with lipid profile. The relationship of IL-33 with CRP and troponin was non-significant.

scholarly journals Serum levels of total sialic acid and lipid profile with the severity of the vessel in patients with non-smoker and diabetic coronary artery disease

2020 ◽  
Vol 42 (5) ◽  
pp. 494-500
Author(s):  
Fatemeh Khaki-Khatibi
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Sialic Acid ◽  
Family History ◽  
Serum Level ◽  
Serum Levels ◽  
Control Group ◽  
Total Sialic Acid ◽  
Significant Difference ◽  
Artery Disease

Background: Coronary Artery Disease (CAD) is a major cause of mortality in most countries. Many risk factors such as high blood pressure, hyperlipidemia, diabetes, age, sex, obesity, smoking, and family history play a role in CAD. The aim of this study was to evaluate the concentration of Total Sialic Acid (TSA) and Lipid Profiles (LP) with the Severity of the Vessel in patients with non-smoker and diabetic CAD, so that by measuring these parameters, effective help for diagnosis and prevention for healthy people Prone to CAD, and also control the treatment of patients. Methods: In this study, 200 individual including 160 patient and 40 control group were considered. All patient groups were non-smokers and diabetic. Patients were divided into 4 groups according to the results of angiography: Patients with Normal angiography (n = 40) with one eclipse (n = 40), patients with double stenosis (n = 40) and patients with eclipse Three vessels (n = 40). The control group was chosen from people who had no history of CAD and other diseases. The lipid profile was measured by standard methods and serum total sialic acid was measured by ELISA method. Results: There was no significant difference between the two groups in age and sex, but there was a significant difference in family history (p<0.05). There was a significant difference in serum glucose level between the patient and the control group (p<0.05), Also hs-CRP serum levels were normal in two patient and control groups. Serum levels of cholesterol, triglyceride and LDL in patient group were significantly higher than that of the control group but HDL serum level was adverse (p <0.05), Also TSA serum level in the patient group was significantly higher than the control group (p<0.05). Conclusion: Serum Total Sialic Acid level in non-smoker and diabetic CAD patients has a significant increase compared to the control group. It seems that the above biochemical parameters contribute significantly to the development and progression of atherosclerosis and CAD, by which timely measurements of these parameters in healthy individual probably can be helpful in preventing and improving CAD and controlling the treatment of patients.

scholarly journals Potential eligibility for low dose rivaroxaban treatment in a “real world” population of Spanish patients with stable coronary artery disease: a subanalysis of the CICCOR registry

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Ruiz Ortiz ◽  
J.J Sanchez Fernandez ◽  
C Ogayar Luque ◽  
E Romo Penas ◽  
M Delgado Ortega ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Real World ◽  
Cardiovascular Events ◽  
Low Dose ◽  
Stable Coronary Artery Disease ◽  
Inclusion Criteria ◽  
Exclusion Criteria ◽  
Artery Disease

Abstract Background In the COMPASS trial, low dose rivaroxaban (2.5 mg/12h) on top of aspirin showed a 26% reduction in major cardiovascular events in patients with stable coronary artery disease (sCAD). However, information about external applicability of these results is limited. Our objective was to assess potential eligibility for this treatment in a “real world” cohort of Spanish patients with sCAD and to evaluate the incidence of major events in the long-term follow up in this population. Methods The CICCOR registry (“Chronic ischemic heart disease in Cordoba”, in Spanish “Cardiopatía isquémica crόnica en Cordoba”) is a prospective, monocentric study. From February 1, 2000 to January 31, 2004, all consecutive patients with sCAD attended at two outpatient cardiology clinics in a city of the south of Spain were included in the study and prospectively followed. The COMPASS inclusion and exclusion criteria were applied to this cohort, and the proportion of patients potentially eligible for this trial was described. The rate of the main COMPASS end-point (the composite of acute myocardial infarction, stroke, or cardiovascular death), as well as mortality rates, were investigated in this subset of patients, and compared with those of sCAD patients included in the aspirin alone group of the COMPASS trial. Results From a total population of 1268 patients, 1246 subjects presented enough data to assess eligibility. Among these, 575 patients (46%) had exclusion criteria, and another 229 (18%) did not fulfill the inclusion criteria and were not eligible. The main reasons for exclusion were requirement for dual antiplatelet therapy within 1 year of an acute coronary syndrome or coronary stent implantation (70%), high-bleeding risk (33%), other non-aspirin antiplatelet therapy (13%), atrial fibrillation (12%), anticoagulant use (11%), history of ischemic stroke (5%) and heart failure with severe left ventricular dysfunction (4%). The reason for not fulfilling inclusion criteria was the absence of additional high risk factors in patients younger than 65 years. The potentially eligible population included 442 patients (35% of evaluable patients), with up to 17 years of follow-up (median 9 years, IQR 4–15 years, only 1 patient lost in follow-up, 4174 patients-years of observation). These patients experienced higher primary outcome event rates than coronary patients actually enrolled in the aspirin alone arm of COMPASS (5.1% versus 2.9% per year), and higher rates of cardiovascular (4.0% versus 1.1%) and all-cause mortality (6.3 versus 2.1%, p&lt;0.00005 for all comparisons). Conclusion More than one third of “real world” patients with sCAD of this prospective Spanish registry could be potentially eligible for low dose rivaroxaban therapy, according to COMPASS inclusion and exclusion criteria. This population had a higher risk of cardiovascular events and mortality than COMPASS participants with sCAD in the reference aspirin group. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document